CO6251276A2 - Formulacion de antraciclina de baja viscosidad - Google Patents

Formulacion de antraciclina de baja viscosidad

Info

Publication number
CO6251276A2
CO6251276A2 CO09144074A CO09144074A CO6251276A2 CO 6251276 A2 CO6251276 A2 CO 6251276A2 CO 09144074 A CO09144074 A CO 09144074A CO 09144074 A CO09144074 A CO 09144074A CO 6251276 A2 CO6251276 A2 CO 6251276A2
Authority
CO
Colombia
Prior art keywords
group
anthracycline
formulation
compound
formulation according
Prior art date
Application number
CO09144074A
Other languages
English (en)
Inventor
Felix Kratz
Original Assignee
Ktb Tumorforschungsgesellschatf Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ktb Tumorforschungsgesellschatf Mbh filed Critical Ktb Tumorforschungsgesellschatf Mbh
Publication of CO6251276A2 publication Critical patent/CO6251276A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Formulación que comprende un compuesto antraciclina y un compuesto heterocíclico o aromático. 2.- Formulación de acuerdo con la reivindicación 1 en la que el compuesto antraciclina es un derivado antraciclina derivado de doxorubicina, daunorubicina, epirubicina, idarubicina, pirarubicina, zorubicina, aclarubicina o carminomicina. 3.- Formulación de acuerdo con cualquiera de las reivindicaciones anteriores en la que el compuesto antraciclina es un derivado hidrazona de antraciclina. 4.- Formulación de acuerdo con cualquiera de las reivindicaciones anteriores en la que el derivado antraciclina tiene la Fórmula general en donde R1 es OCH3, OC2H5, H o OH1 R2 es una glicosida, R4 y R5 son independiente H, OH, alquilo C1-C4, en particular, C2H5, Oalquilo C1-C4 o C(CH2R3) =N-NH-CO-X-Y, en donde R3 es H o OH, X es un grupo de ligado, en particular, -(CH2)n-, -(CH2)n-C6H4- o -C6H4-, en donde n = 1-12, y Y es un grupo de unión, en particular, un grupo maleinimida, un grupo acetato de amida halógeno, un grupo acetato de halógeno, un grupo piridilditio, un grupo éster N-hidroxisuccinimida, grupo isotiocianato, un grupo disulfuro, un grupo vinilcarbonilo, un grupo aziridina o un grupo acetileno, con la condición que por lo menos uno de R4 y R5 es C(CH2R3) = N-NH-CO-X-Y.
CO09144074A 2007-05-16 2009-12-16 Formulacion de antraciclina de baja viscosidad CO6251276A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07009865 2007-05-16

Publications (1)

Publication Number Publication Date
CO6251276A2 true CO6251276A2 (es) 2011-02-21

Family

ID=39705201

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09144074A CO6251276A2 (es) 2007-05-16 2009-12-16 Formulacion de antraciclina de baja viscosidad

Country Status (11)

Country Link
US (1) US8703724B2 (es)
EP (1) EP2152312B1 (es)
JP (1) JP5634862B2 (es)
KR (1) KR20100029764A (es)
CN (1) CN101743020A (es)
AU (1) AU2008250518B2 (es)
BR (1) BRPI0811248A2 (es)
CA (1) CA2687291A1 (es)
CO (1) CO6251276A2 (es)
MX (1) MX2009012370A (es)
WO (1) WO2008138646A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846882B2 (en) * 2011-04-29 2014-09-30 Synbias Pharma Ag Method of producing 4-demethoxydaunorubicin
WO2013154045A1 (ja) * 2012-04-09 2013-10-17 日本マイクロバイオファーマ株式会社 注射剤用組成物
AU2013359048A1 (en) * 2012-12-13 2015-07-02 Cytrx Corporation Anthracycline formulations
AU2014274940B2 (en) 2013-06-05 2019-05-23 Cytrx Corporation Cytotoxic agents for the treatment of cancer
CN104434818B (zh) * 2014-11-08 2017-08-08 山东新时代药业有限公司 一种注射用盐酸柔红霉素
ES2909486T3 (es) * 2015-06-19 2022-05-06 Centurion Biopharma Corp Sistemas de administración para liberación controlada de fármaco
CA3083985A1 (en) 2017-11-30 2019-06-06 Centurion Biopharma Corporation Maytansinoid-based drug delivery systems
US11377473B2 (en) 2017-11-30 2022-07-05 Centurion Biopharma Corporation Albumin-binding prodrugs of auristatin E derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US5157044A (en) * 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5166319A (en) 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
EP0493745A1 (en) 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2915252B2 (ja) * 1993-06-30 1999-07-05 明治製菓株式会社 溶解性が改善された製剤の製造法
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
US5612474A (en) * 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
WO2000002050A1 (en) 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
IT1282625B1 (it) 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
EP1007533B1 (en) 1996-08-27 2005-06-22 University Of Utah Research Foundation Bioconjugates and delivery of bioactive agents
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
DE19923168A1 (de) 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
WO2003018056A1 (fr) * 2001-08-29 2003-03-06 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
ES2337563T3 (es) * 2002-12-31 2010-04-27 Zydus Bsv Pharma Private Limited Liposomas no pegilados de circulacion duradera.

Also Published As

Publication number Publication date
WO2008138646A1 (en) 2008-11-20
US8703724B2 (en) 2014-04-22
KR20100029764A (ko) 2010-03-17
AU2008250518B2 (en) 2013-09-12
JP5634862B2 (ja) 2014-12-03
BRPI0811248A2 (pt) 2014-11-04
MX2009012370A (es) 2010-04-22
JP2010526845A (ja) 2010-08-05
US20100152273A1 (en) 2010-06-17
EP2152312A1 (en) 2010-02-17
EP2152312B1 (en) 2014-12-31
CN101743020A (zh) 2010-06-16
AU2008250518A1 (en) 2008-11-20
CA2687291A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
CO6251276A2 (es) Formulacion de antraciclina de baja viscosidad
WO2009046314A3 (en) Moenomycin analogs, methods of synthesis, and uses thereof
ECSP099403A (es) Formulacion parenteral del anticuerpo abeta
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CL2010001056A1 (es) Mezclas pesticida que comprende el derivado de antranilamida 3- bromo-n- [4-ciano-2- metil-6-[( metilamino)- carbonil]fenil] -1-(3 cloro -2-piridinil)- 1h - pirazol-5- carboxamida y al menos una lactona macrociclica; composiciones y metodo que emplean dicha mezcla para combatir plagas de invertebrados. (divisional de la solicitud 1856-05)
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GT200600223A (es) Tigeciclina y metodos para preparar 9-nitrominociclina
CR8402A (es) Indazol-o-glucosidos sustitutos
GT200600181A (es) Derivados de amida sustituida y metodos de uso
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
BRPI0813450B8 (pt) composto, formulação farmacêutica, e, usos do composto
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
AR066476A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
GT200400133A (es) Derivados de pirrolo[3,4-c] pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
ECSP088905A (es) Nuevos compuestos
UY30030A1 (es) Derivados sustituidos de la 8-piracin-2-il-1,2,4,4a-tetrahidro-2´h, 6h-espiro (1,4-oxacin(4,3-a)quinolin-5,5´-pirimidin)-2´, 4´, 6´ (1´h, 3´h)-tiona, composiciones y aplicaciones
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
BRPI0519679A2 (pt) misturas de azocorantes dispersos
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
EP1188769A8 (en) High resolution crystal structure of the ribosome and design of protein synthesis inhibitors
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
UY30187A1 (es) Nuevas modificaciones cristalinas y solvato

Legal Events

Date Code Title Description
FA Application withdrawn